compound, methods for treating or preventing disorders, diseases or conditions responsive to melanocortin-4 receptor activation, for treating or preventing obesity, for treating or preventing an obesity-related disorder, for treating or preventing of diabetes mellitus, for the treatment or prevention of male or female sexual dysfunction and for the treatment or prevention of erectile dysfunction, pharmaceutical composition, methods for the treatment of erectile dysfunction in a mammal, for the treatment of diabetes in a mammal and for obesity treatment in a mammal, and, use of a compound

摘要

"COMPOSITION, METHODS FOR TREATMENT OR PREVENTION OF DISORDERS, DISEASES OR CONDITIONS RESPONSIBLE FOR THE ACTIVATION OF THE MELANOCORTIN-4 RECEIVER FOR THE TREATMENT OR PREVENTION OF OBESITY, FOR THE TREATMENT OR PREVENTION OF A RELATED DISORDER PREVENTION OF DIABETIC MELITE, FOR THE TREATMENT OR PREVENTION OF MALE OR FEMALE SEXUAL DYSFUNCTION AND FOR THE TREATMENT OR PREVENTION OF ERECTIVE DIFFERENCE, METHODS FOR TREATING DIFFERENTIAL AND MERIFIED DIFFERENCE, AND METHODS Treating Obesity In A Mammalian, And Using A Compound ". Certain novel N-acylated spiropiperidine derivatives are human melanocortin receptor (s) agonists and, in particular, are selective human melanocortin-4 receptor (MC-4R) agonists. They are therefore useful for the treatment, control or prevention of diseases and disorders responsive to MC-4R activation, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.